These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21857161)

  • 1. Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis.
    Wang J; Liu Y; Tan LX; Lo JC; Du J; Ryu MJ; Ranheim EA; Zhang J
    Cell Cycle; 2011 Sep; 10(17):2836-9. PubMed ID: 21857161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
    Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; Passegué E; Shannon K; Braun BS
    PLoS Biol; 2009 Mar; 7(3):e59. PubMed ID: 19296721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
    Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
    Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.
    Wang J; Kong G; Liu Y; Du J; Chang YI; Tey SR; Zhang X; Ranheim EA; Saba-El-Leil MK; Meloche S; Damnernsawad A; Zhang J; Zhang J
    Blood; 2013 Jun; 121(26):5203-7. PubMed ID: 23687087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.
    Wang J; Liu Y; Li Z; Wang Z; Tan LX; Ryu MJ; Meline B; Du J; Young KH; Ranheim E; Chang Q; Zhang J
    Blood; 2011 Jul; 118(2):368-79. PubMed ID: 21586752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
    Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis.
    Karra L; Romero-Moya D; Ksionda O; Krush M; Gu Z; Mues M; Depeille P; Mullighan C; Roose JP
    Oncogene; 2020 Nov; 39(45):6920-6934. PubMed ID: 32989257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.
    Li Q; Bohin N; Wen T; Ng V; Magee J; Chen SC; Shannon K; Morrison SJ
    Nature; 2013 Dec; 504(7478):143-147. PubMed ID: 24284627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
    Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
    J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.
    Zhang J; Wang J; Liu Y; Sidik H; Young KH; Lodish HF; Fleming MD
    Blood; 2009 Feb; 113(6):1304-14. PubMed ID: 19066392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.
    Kong G; Chang YI; Damnernsawad A; You X; Du J; Ranheim EA; Lee W; Ryu MJ; Zhou Y; Xing Y; Chang Q; Burd CE; Zhang J
    Leukemia; 2016 Jul; 30(7):1542-51. PubMed ID: 27055865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.
    Zhang J; Ranheim EA; Du J; Liu Y; Wang J; Kong G; Zhang J
    J Biol Chem; 2015 Jul; 290(31):19093-103. PubMed ID: 26082490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique dependence on Sos1 in
    You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
    Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.
    Xu D; Wang S; Yu WM; Chan G; Araki T; Bunting KD; Neel BG; Qu CK
    Blood; 2010 Nov; 116(18):3611-21. PubMed ID: 20651068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
    Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
    Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic N-Ras Mitigates Oxidative Stress-Induced Apoptosis of Hematopoietic Stem Cells.
    Ney GM; Yang KB; Ng V; Liu L; Zhao M; Kuk W; Alaka L; Sampang L; Ross A; Jones MA; Jin X; McKay LM; Evarts H; Li Q
    Cancer Res; 2021 Mar; 81(5):1240-1251. PubMed ID: 33441311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.
    Zhang J; Kong G; Rajagopalan A; Lu L; Song J; Hussaini M; Zhang X; Ranheim EA; Liu Y; Wang J; Gao X; Chang YI; Johnson KD; Zhou Y; Yang D; Bhatnagar B; Lucas DM; Bresnick EH; Zhong X; Padron E; Zhang J
    Blood; 2017 Jan; 129(3):358-370. PubMed ID: 27815262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells.
    Jin X; Qin T; Zhao M; Bailey N; Liu L; Yang K; Ng V; Higashimoto T; Coolon R; Ney G; Figueroa ME; Li Q
    Blood Adv; 2018 Jun; 2(11):1259-1271. PubMed ID: 29866713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals.
    Du J; Liu Y; Meline B; Kong G; Tan LX; Lo JC; Wang J; Ranheim E; Zhang L; Chang YI; Ryu MJ; Zhang JF; Zhang J
    Leukemia; 2013 Mar; 27(3):754-7. PubMed ID: 22976127
    [No Abstract]   [Full Text] [Related]  

  • 20. NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.
    Aydin E; Hallner A; Grauers Wiktorin H; Staffas A; Hellstrand K; Martner A
    Oncogene; 2019 Feb; 38(9):1534-1543. PubMed ID: 30323311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.